share_log

叮噹健康：截至2024年12月31日止年度年度業績公告

DINGDANG HEALTH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024

HKEX ·  Mar 21 12:20

Summary by Moomoo AI

叮噹健康科技集團2024財年總收入為人民幣46.69億元，同比下降3.9%。年內淨虧損擴大至人民幣3.80億元，同比增加64.6%，主要由於計提商譽減值損失人民幣1.99億元及其他無形資產減值損失687萬元。毛利率上升至32.9%，較去年同期的31.1%有所改善。公司線上直營收入同比下降7.2%至人民幣32.75億元，業務分銷收入增長17.8%至人民幣6.43億元，線下零售收入下降3.4%至人民幣6.22億元。期內公司主動調整業務佈局，暫停了重慶、南京、濟南及福州等城市的智慧藥房連鎖經營，將資源聚焦於北京、上海、深圳等核心城市。展望未來，公司將持續鞏固北京、上海、深圳等主要城市的服務優勢，加強在供應鏈端的產業優勢。同時，公司將積極推進醫保線上支付試點，已在北京、上海、深圳、佛山等地部分智慧藥房開通線上醫保購藥服務，並持續打造「醫、檢、藥、險」的服務生態體系。
叮噹健康科技集團2024財年總收入為人民幣46.69億元，同比下降3.9%。年內淨虧損擴大至人民幣3.80億元，同比增加64.6%，主要由於計提商譽減值損失人民幣1.99億元及其他無形資產減值損失687萬元。毛利率上升至32.9%，較去年同期的31.1%有所改善。公司線上直營收入同比下降7.2%至人民幣32.75億元，業務分銷收入增長17.8%至人民幣6.43億元，線下零售收入下降3.4%至人民幣6.22億元。期內公司主動調整業務佈局，暫停了重慶、南京、濟南及福州等城市的智慧藥房連鎖經營，將資源聚焦於北京、上海、深圳等核心城市。展望未來，公司將持續鞏固北京、上海、深圳等主要城市的服務優勢，加強在供應鏈端的產業優勢。同時，公司將積極推進醫保線上支付試點，已在北京、上海、深圳、佛山等地部分智慧藥房開通線上醫保購藥服務，並持續打造「醫、檢、藥、險」的服務生態體系。
Dingdong Health Technology Group's total revenue for the fiscal year 2024 is 4.669 billion yuan, a year-on-year decrease of 3.9%. The net loss for the year expanded to 0.38 billion yuan, an increase of 64.6% year-on-year, mainly due to the recognition of goodwill impairment losses of 0.199 billion yuan and other intangible asset impairment losses of 6.87 million yuan. The gross margin rose to 32.9%, an improvement from 31.1% in the same period last year.The company's online direct sales revenue decreased by 7.2% to 3.275 billion yuan, while distribution revenue increased by 17.8% to 0.643 billion yuan, and offline retail revenue decreased by 3.4% to 0.622 billion yuan. During the period, the company proactively adjusted its business layout, suspending the operation of smart pharmacy chains in cities such...Show More
Dingdong Health Technology Group's total revenue for the fiscal year 2024 is 4.669 billion yuan, a year-on-year decrease of 3.9%. The net loss for the year expanded to 0.38 billion yuan, an increase of 64.6% year-on-year, mainly due to the recognition of goodwill impairment losses of 0.199 billion yuan and other intangible asset impairment losses of 6.87 million yuan. The gross margin rose to 32.9%, an improvement from 31.1% in the same period last year.The company's online direct sales revenue decreased by 7.2% to 3.275 billion yuan, while distribution revenue increased by 17.8% to 0.643 billion yuan, and offline retail revenue decreased by 3.4% to 0.622 billion yuan. During the period, the company proactively adjusted its business layout, suspending the operation of smart pharmacy chains in cities such as Chongqing, Nanjing, Jinan, and Fuzhou, and focusing resources on core cities like Peking, Shanghai, and Shenzhen.Looking ahead, the company will continue to strengthen its service advantages in major cities like Peking, Shanghai, and Shenzhen, enhancing its industrial advantages on the supply chain end. At the same time, the company will actively promote the pilot of online payment for medical insurance, having already launched online medical insurance drug purchase services in some smart pharmacies in Peking, Shanghai, Shenzhen, Foshan, and continues to build a service ecosystem of 'medical, inspection, pharmacy, insurance.'

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 298

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
JD HEALTH
06618
33.350
KINGWORLD
01110
0.450
FANGZHOU JIANKE
06086
4.850
SINOPHARM
01099
18.400
ALI HEALTH
00241
4.950
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Fed rate cut expectations for 2025 intensify. What’s your market outlook?
44%
56%
Bullish
Bearlish
1577 votes
FOMC Press Conference, March 19, 2025

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK